Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 24451-24460 Newer>

The Motley Fool July 12, 2007 Rick Aristotle Munarriz	Dueling Fools: eBay Bear Rebuttal Investors, eBay doesn't get "it" anymore. What does it really mean if eBay is struggling even as competitors are falling by the wayside?
The Motley Fool July 12, 2007 Rick Aristotle Munarriz	Dueling Fools: eBay Bear This is not a company you want to overpay for. No, it's not worth as little as a free Kijiji ad.
The Motley Fool July 12, 2007 Tim Beyers	Dueling Fools: eBay Bull Yes, eBay is potentially expensive at 39 times trailing earnings. But it was also expensive at 97 times earnings. Look what's happened since.
The Motley Fool July 12, 2007 Ryan Fuhrmann	Foolish Forecast: Franklin Covey Looks for Motivation The corporate trainer and consulting company is set to release it third-quarter earnings. Investors, here is what you can expect to see.
The Motley Fool July 12, 2007 Ryan Fuhrmann	Change Afoot at Fastenal Continued improvement in the industrial and construction supplier's operational performance boosts second-quarter earnings.
The Motley Fool July 12, 2007 Tom Taulli	Infosys Still Rocked by the Rupee The Indian consulting firm continues to battle wage pressures and a higher currency. So far this year, Infosys' stock price has been lackluster.
The Motley Fool July 12, 2007	Mercantile Non-Performs: Fool by Numbers The regional bank released second-quarter 2007 earnings: Income Statement Highlights... Ratio Checkup... Balance Sheet Highlights...
The Motley Fool July 12, 2007 Tim Beyers	I See TiVo's Future How tough has it been to be a TiVo shareholder? This tough.
The Motley Fool July 12, 2007 Ryan Fuhrmann	Nobody's Home at Fleetwood Enterprises It will be an even longer road to recovery for manufactured housing and RV company. Investors, take note.
The Motley Fool July 12, 2007 Brian Lawler	Noven's Novel Acquisition With JDS Pharmaceuticals, the company is moving toward more traditional oral drugs. Investors, take note.
<Older 24451-24460 Newer> Return to current articles.